5 billion in cash.

Solvay’s business will also provide us a platform to enter the attractive global vaccines market. Financial Highlights The deal will be approximately $0.10 accretive to ongoing earnings per share this year 2010, accelerating to more than $0.20 by 2012, increasing thereafter, all before one-period transaction-related items, which will be provided at a later time. These one-time transaction-related products are expected that occurs between 2010 and 2012. The deal also includes payments as high as EUR 300 million if certain sales milestones are fulfilled between 2011 and 2013. Abbott plans to fund the transaction with cash on the total amount sheet currently. This transaction is at the mercy of customary closing conditions and regulatory approvals and can be expected to close in the first quarter of 2010.Computed tomography images demonstrated the continuum of the mass with the proper colon. Dr. Kabay and his surgical group scheduled their patient for a laparotomy under general anesthesia. Through the operation, the medical team was thrilled to diagnose the double tubular colon as the cause of the pathological mass. The mass with duplicated colon and appendix was removed uneventfully. The postsurgical span of the patient was not significant and he recovered more than the following season. In an effort to make the correct diagnosis in the patient, Dr. Kabay and Dr. Yaylak were forced to carry out a fine pre-operative diagnostic workup.